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Abstract
Gerstmann-Sträussler-Scheinker (GSS) P102L disease is a familial form of a transmissible
spongiform encephalopathy (TSE) that can present with or without vacuolation of neuropil.
Inefficient disease transmission into 101LL transgenic mice was previously observed from GSS
P102L without vacuolation. However several aged, healthy mice had large plaques composed of
abnormal prion protein (PrPd). Here we perform the ultrastructural characterisation of such
plaques and compare them with PrPd aggregates found in TSE caused by an infectious
mechanism. PrPd plaques in 101LL mice varied in maturity with some being composed of deposits
without visible amyloid fibrils. PrPd was present on cell membranes in the vicinity of all types of
plaques. In contrast to the unicentric plaques seen in infectious murine scrapie the plaques seen in
the current model were multi-centric and were initiated by proto-fibrillar forms of PrPd situated on
oligodendroglia, astrocytes and neuritic cell membranes. We speculate that the initial conversion
process leading to plaque formation begins with membrane-bound PrPC but that subsequent
fibrillisation does not require membrane attachment. We also observed that the membrane
alterations consistently seen in murine scrapie and other infectious TSEs were not observed in
101LL mice with plaques suggesting differences in the pathogenesis of these conditions.
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Introduction
Prion diseases or transmissible spongiform encephalopathies (TSEs) are a group of fatal
neurodegenerative disorders that affect domestic farm animals, wild cervids, farmed mink
and man. TSEs may be infectious under natural conditions or have an idiopathic or an
iatrogenic cause, while in man they may also occur as a familial disorder (12). The
pathological features of prion disease are usually cited as neuropil vacuolation, neuronal loss
Corresponding author M Jeffrey; m.jeffrey@vla.defra.gsi.gov.uk; tel 0131 445 6169; fax 0131 445 6166.
NIH Public Access
Author Manuscript
Brain Pathol. Author manuscript; available in PMC 2013 January 1.
Published in final edited form as:
Brain Pathol. 2012 January ; 22(1): 58–66. doi:10.1111/j.1750-3639.2011.00508.x.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
and gliosis. Prion diseases are characterised by the post translational conversion of a host
encoded cellular isoform of prion protein (PrPc) into pathologic isoforms (39) that may form
amyloid plaques in affected subjects. Disease associated PrP may be detected by
biochemical methods that involve a partial protease digestion step (PrPres) while
immunohistochemical methods reveal a variety of different membrane forms, aggregation
states, and both protease resistant and protease sensitive forms of PrP (PrPd). It is commonly
thought that the pathologic isoforms of PrP may be infectious in the absence of nucleic acids
(39). However, it is increasingly recognised that the correlation between PrPd or PrPres and
infectivity is inexact (2, 3, 29, 38, 40). To accommodate discrepancies between PrPd or
PrPres detection and infectivity, it has been proposed that sub-populations of abnormal PrP
isofoms may exist that are pathogenic, protease sensitive and infectious while others are
partially protease resistant and pathogenic but are not infectious (38, 43).
Gerstmann-Sträussler-Scheinker (GSS) disease is a familial prion disease associated with a
variety of different mutations of the human prion protein gene (PRNP). Brains from human
patients with some GSS mutations transmit a prion like disease to rodents or to primates (for
review see (11) ). One of the most studied GSS diseases is the proline to leucine mutation at
codon 102 (P102L) (12). Two distinct phenotypes of GSS P102L disease have been
described (36). In one phenotype PrPres accumulates as 21 kDa and 8 kDa fragments, and is
associated with vacuolation of the neuropil (35, 36) and transmissibility to wild type mice
commonly used for laboratory bioassay (42) and PrP transgenic mouse lines (33, 38). The
second disease phenotype is associated with only an 8 kDa PrPres fragment and no neuropil
vacuolation (36). When brain extracts from GSS P102L patients with 8kDa fragments and
no vacuolation (PrP-8) are inoculated into wild type mice, no disease occurs. When such
tissues are used to challenge a gene targeted transgenic mouse line which are homozygous
for leucine at codon 101 (101LL; the mouse homologue of human codon 102) inefficient
disease transmission is observed. However, several asymptomatic mice accumulate PrP
amyloid plaques (101LL-8a mice), but do not replicate the TSE infectious agent. No
neurological signs or vacuolation of the neuropil was observed in 101LL-8a mice on
primary or subsequent sub-passage. However, recipient 101LL-8a mice also showed PrP
amyloid accumulation on sub-passage (38). These amyloid plaques are composed of murine
PrPres suggesting that the human 8kDa P102L PrPres can convert murine 101L PrPc into
murine PrP amyloid without creating infectivity or TSE. Thus 101LL-8a mice provide a
model of mutant PrP interactions that result in amyloid plaque formation but no clinical
disease or spongiform change.
That the conversion of host PrPc to PrPd may occur in the absence of infectivity is of some
fundamental interest. Infectious TSEs of animals show a number of specific, mostly
membrane related pathological changes (25). Cattle BSE, sheep scrapie, feline spongiform
encephalopathy and different murine scrapie models all show membrane PrPd accumulation
associated with increased numbers of bizarre clathrin coated vesicles and clefts of dendrites,
spiral membrane invaginations of axon terminals, membrane microfolding and increased
lysosomes in brain (25). Some of these changes have been also been described in human
TSEs but their co-localisation with PrPd has not yet been confirmed. In this study we have
sought to determine whether sub-cellular features of pathological changes that uniquely
occur in infectious TSEs are also present in 101LL-8a mice and to study the nature of the
conversion process of 101LL PrPc into amyloid. We show that unlike PrPd accumulations
found in most naturally infectious forms of TSEs, 101LL-8a mice form amyloid fibrils
without such membrane pathology. We further show that fibrils are generated from putative
protofilaments by recruitment of PrPc molecules attached to cell membranes.
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Materials and methods
The generation of 101LL mice (33) and the results after inoculation of PrP-8 has previously
been described (38). The human brain tissue used in these original studies was obtained with
full consent of the patient’s family for use in research. All mouse experiments were
reviewed and approved by the Local Ethical Review Committee and performed under
license from the United Kingdom Home Office in accordance with the United Kingdom
Animals (Scientific Procedures) Act 1986.
Brains from 14 101LL-8a mice at more that 400 days after intracerebral challenge with brain
homogenate from mice previously challenged with 8kDa GSS P102L(101LL-8a mice) were
embedded in paraffin wax, cut and labeled with antibodies raised to mouse PrP by methods
in routine use in our laboratory (14). The R18 antibody was raised against amino-acid
sequence (aa) 142-155; R20 to aa 218-232; R24 to aa 23-37 and R30 to aa 89-103 as
previously reported (6). The number and location of plaques in five coronal whole brain or
hemi-brain slices, two of which contained representation of the corpus callosum, were
recorded in each mouse.
An additional four 101LL mice inoculated with brain homogenate from 101LL-8a mice
were killed at 626-638 days of age post challenge together with three unchallenged age
matched controls. These mice were perfused with 4% paraformaldehyde and 0.1%
glutaraldehyde for study by electron microscopy and their brains were serially coronally
sectioned at 1mm intervals. Alternate serial 1mm brain slices were then embedded in
paraffin wax, sectioned and immuno-labeled for PrPd to confirm the presence and
distribution of plaques by light microscopy. Other brain slices were further sectioned to
1mm3 samples. These tissue blocks were post-fixed in osmium tetroxide, dehydrated and
embedded in epon resin for electron microscopy. Between 21 and 30 one mm3 cube blocks
of brain tissue (cerebellum, thalamus and hippocampus) were taken from each mouse.
101LL mice develop disease when challenged with brains of GSS P102L patients that
demonstrate vacuolation and accumulation of both 21kDa and 8kDa PrPres fragments (38).
However such mice do not reliably develop plaques and plaques could not be found in
samples prepared from three such mice prepared for electron microscopy. 87V scrapie is an
infectious murine scrapie strain which produces accumulation of numerous PrPd plaques in
VM mice (19). Only higher molecular weight fragments of PrPres and not the 8kDa PrPres
fragment can be demonstrated from brains of mice with 87V scrapie (19). Accordingly, 87V
murine scrapie and unchallenged transgenic mice were used as controls.
Our previous experience indicates that not all antibodies able to detect PrPd in wax
embedded tissues can reveal PrPd in tissues embedded in plastic (18).To identify antibodies
for use in immunogold electron microscopy a range of antibodies were tested in wax and
plastic embedded tissues. The following anti-PrP monoclonal antibodies were selected for
testing: i) BG4 and Saf32, which were raised against bovine recombinant PrP aa 23-85 or
sheep aa 62-90 respectively and both recognize sequences within the octapeptide repeat
region that are conserved in the mouse; ii) Saf 84, Sha 31 and 2G11 raised against different
PrP aa 145-182 of the sheep sequence; iii) polyclonal rabbit antibodies R486 raised against
bovine PrP aa 217-231 and 1A8 raised against a murine scrapie-associated fibril preparation.
Each of the above antibodies was able to recognize PrPd in wax embedded tissues of
101LL-8a mice. PrPd plaques in plastic embedded tissues were only revealed by 1A8, R486
and Saf 84 antibodies. Therefore, the other antibodies listed above were not taken though to
immunogold electron microscopy and will not be discussed further.
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Sections obtained from wax embedded tissues were also labeled by immunohistochemistry
for glial fibrillary acidic protein (Dako Uk ltd). Additional sections were stained by
haematoxylin and eosin, by periodic acid Schiff reaction or by Congo red methods.
Electron microscopy procedure
Resin embedded sections were cut at 1μm and stained with toluidine blue or labeled with
1A8, R486 or Saf 84. Tissues from mice infected with 87V scrapie were available as
positive controls. As described previously (34) the avidin-biotin complex
immunohistochemical staining method was applied to the etched and pre-treated sections.
Uni-centric plaques and plaques with multi-centric cores were identified in several tissue
blocks taken from each of three 101LL-8a mice. Sections from five blocks, each containing
from one to five plaques, were then serially sectioned at 60nm and stained using uranyl
acetate and lead citrate. Sections were then immuno-labelled for PrPd using 1A8, Saf84 or
R486 antibodies by immunogold methods as previously described (34).
Using these post-embedding immunogold methods, no immuno-labelling is found in control
mouse brains (not shown). Thus PrPc is not detected in normal mouse brains (not shown) by
the post-embedding methods employed here and all immuno-labelling found in disease
affected brains is interpreted as PrPd.
Results
Light microscopy
Where serial sections of brains embedded in paraffin wax were examined, 10 of 14
101LL-8a mice showed the presence of PrPd plaques. In all but two mice, plaques were
located in or adjacent to the corpus callosum. The remaining plaques found in two mice
were within the internal capsule, adjacent to the pia of the ventral hippocampus or dorsal
thalamus and within the stratum lacunosum of the hippocampus. Only hemi-brain slices
were available from most mice but a bilateral distribution of plaques was confirmed in two
mice where whole brains were available. Plaques in the hemisphere contra-lateral to the
injection hemisphere were also located in the corpus callosum. The pattern of labelling of
plaques was the same for each of the antibodies used in this study. While a proportion of
plaques showed uniform labelling, most showed a weaker immunoreactivity in the core of
the plaques and a stronger labelling intensity in the plaque periphery (Fig 1). This pattern
was the same for C- (R18, R20, R30, R486, 1A8, Saf 84, Sha 31 2G11) and N-terminal
(R24; BG4; Saf 32) antibodies, and for tissues fixed in formaldehyde and embedded in
paraffin wax or fixed in mixed aldehydes and embedded in paraffin wax or in plastic. In
contrast with the plaques in 101LL-8a mice, plaques from 87V infected mice were
consistently and uniformly labelled with all antibodies tested in both core and periphery (Fig
1).
A range of plaque morphology was seen in 101LL-8a mice. Some large uni-centric plaques
were round or ovoidal while other multi-centric plaques consisted of a large dense core
surrounded by smaller irregular areas of labelling (Fig 1a). Multifocal groups of plaques and
localised peri-cellular PrPd labelling patterns were also seen (Fig 1b). When the numbers of
plaques were compared in HE or toluidine blue labelled sections and in serial immuno-
labelled sections, many fewer plaques were detected by tinctorial staining methods. More
plaques were also seen on immuno-labelled sections when compared to sections stained by
the periodic-acid Schiff reaction or by Congo red, suggesting that not all plaques were
composed of mature amyloid arranged into bundles.
87V plaques had the classical stellate appearance and were not multi-centric.
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Electron microscopy 101LL-8a: uranyl acetate-lead citrate staining
Some plaques were entirely contained within the corpus callosum but many were at the
interface of the ventral border of the corpus callosum and the hippocampus and often spilled
over to involve the stratum oriens. Within the corpus callosum plaques were situated
between planes of white matter where one group of myelinated processes was running at an
angle different from an adjacent bundle. Often the plaques were located around or near
blood vessels. Plaques entirely located within white matter of the corpus callosum were
surrounded by reactive astrocytes or oligodendroglia. Microglia were infrequent in white
matter plaques but were more prominent around plaques that extended into the stratum
oriens of the hippocampal grey matter.
Multi-centric plaques were generally composed of a dense core (Fig 2a) and several
peripherally located, similarly sized, satellite sub-units (Fig 2c). The core of large plaques
consisted almost exclusively of densely packed and randomly orientated amyloid fibrils (Fig
2a). Serial sectioning through multi-centric plaques suggested that each satellite sub-unit
derived from a separate core or seed. Thus satellite plaques surrounding large dense parent
plaques appear to be initiated from centrifugally dispersed seeds rather than emanating by
continuous growth from the parent core. A spectrum of maturity of multi-centric plaques
could be inferred from their structure. While older, more mature multi-centric plaques are as
described above, other less mature multi-centric plaques consisted of sub-units possessing
few amyloid fibrils surrounded by reactive glial processes (Fig 2d,e) suggesting a
continuous and ongoing process of seeding and growth.
The periphery of large parent and satellite plaques showed smaller groups of amyloid fibrils
inserted between different cellular processes (Fig 2b) and surrounded by reactive microglia,
astrocytes and large dystrophic neurites (Fig 2f). Dystrophic neurites, which are
characterised by the accumulation of excess organelles including lysosomes and
mitochondria (31), affected both large myelinated fibres and smaller unmyelinated neurites.
Individual dystrophic processes and other degenerative white matter features such as axons
undergoing Wallerian-type degeneration could be found at some considerable distances (at
least 0.5 mm) from a plaque.
Electron microscopy 101LL-8a: immunogold labelling
The cores of plaques in 101LL-8a mice, which consisted of densely packed randomly
orientated fibrils, (that were unstained or lightly stained in 1μm thick sections), were
labelled for PrPd by immunogold methods (Fig 3a). Those cores were labelled successfully
by all three antibodies used 1A8, R486, and by Saf84. Because fibrils in the centre of
amyloid plaques that were unlabelled by antibodies in 1μm plastic embedded sections were
labelled when the same antibody was used on serial immunogold labelled sections cut at
60-80nm thickness, it would appear that the absence of labelling was due to technical issues,
probably related to the highly compact nature of the packing of the amyloid fibrils in these
plaques.
Satellite plaques (Fig 3b) at the periphery of large plaques, consisting of smaller groups of
extracellular amyloid fibrils and smaller multi-centric plaques, also showed labelling for
PrPd with each of the antibodies used. However, PrPd labelling was not confined to amyloid
fibrils. At the extreme periphery of uni-centric plaques and larger multi-centric plaques,
PrPd labelling was found on the cell membranes of processes and on cell bodies in the
absence of visible fibrillar amyloid (Fig 3c). PrPd plasma-lemmal labelling surrounding
plaques located in corpus callosum white matter was found on oligodendroglia (Fig 3c) and
astrocytes (Fig 3d). Where plaques extended to involve grey matter, PrPd membrane
labelling was also seen on dendrites and probably also on axonal membranes.
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Some plaques visible in immuno-labelled 1μm thick sections examined by light microscopy
could not be reliably located by uranyl acetate /lead citrate staining but could be detected
following immunogold labelling for PrPd in serial sections. PrPd labelling of such nascent
plaques consisted of localised areas of membrane and extracellular PrPd signal (Fig 3e). In
uranyl acetate/lead citrate stained sections these plaques could only be found by determining
the location of the plaque in immunogold labelled sections, and then finding the exact same
location in the uranyl acetate/lead citrate stained sections. These nascent plaques showed
none of the pathological changes associated with the more mature plaques: there was no
evidence of amyloid fibrils, gliosis, or neuronal dystrophia and only mild irregularity of
process contours could be identified.
Membrane-associated PrPd in the infectious forms of animal TSEs is associated with several
specific membrane changes (vide infra and (25)). These changes were not found in the
101LL-8a mice. Also present in naturally occurring TSEs and experimental models of
scrapie is lysosomal PrPd accumulation in neuronal perikarya and in astrocytes and
microglia (25). The latter are often particularly abundant around plaques. In the 101LL-8a
mouse, PrPd was absent from lysosomes of astrocytes and microglia.
Dystrophic neurites were not found in the centre of plaques, rather they were predominantly
located at the plaque periphery within areas of neuropil containing small numbers of
amyloid fibrils in the extracellular spaces. Although strong immunogold labelling was
obtained on these amyloid fibrils and on some adjacent cell membranes, PrPd labelling was
not specifically detected on cell membranes of dystrophic neurites, nor was PrPd labelling
found on the cell membranes of oligodendrocytes or axons associated with other
degenerative white matter lesions.
Electron microscopy: 87V scrapie
The morphology and inferred formation of plaques in 87V scrapie was in agreement with
previous descriptions (19,20). Briefly, plaques in 87V scrapie occurred mainly in grey
matter where they appeared to be initiated by accumulation of PrPd at short segments of
dendrite plasma-membranes and then locally released to form small numbers of visible short
amyloid fibrils lying between processes. These short amyloid fibrils elicited marked
astrocytic and microglial responses. With increasing plaque maturity, individual fibrils were
orientated into bundles and plaques took the classic stellate appearance by a centrifugal
growth of these amyloid bundles radiating between cell processes within grey matter
neuropil. Diffuse plaques with fewer fibrils and lacking a stellate arrangement were also
found adjacent to the glial limitans of the sub-pial neuropil and within the thalamus. White
matter plaques were occasionally found in the corpus callosum. Plaques were surrounded by
dystrophic neurites, reactive astrocytes and microglia.
As previously reported, strong PrPd labelling was observed on amyloid fibrils (Fig 4a) (19,
20). PrPd labelling was also found on dendrite membranes of immature plaques and where
only sparse, or no fibrils were seen at the plaque periphery (Fig 4b). Also present at these
locations were microglia and astrocytes with immuno-labelling for PrPd within lysosomes
(Fig 4c). At the extreme periphery of the plaque, membrane changes pathognomonic of
infectious TSEs were also seen (25) (Fig 4d-g). These changes consisted of membrane
protrusions or micro-folding (Fig 4d,e), spiral membrane inclusions in axon terminals (Fig
4f), abnormal dendritic membrane invaginations and excess coated pits (Fig 4g). For a more
complete description of the nature and morphologic variation of these TSE-specific
membrane changes see (25). In addition, other prion specific changes such as so called
tubulovesicular bodies and non-prion specific changes such as axon terminal degeneration
and vacuolation were also present within neuropil in the vicinity of plaques (not shown).
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Discussion
In this study we have shown that the plaques found in 101LL-8a mice consisted not only of
mature plaques composed of densely packed amyloid fibrils, but also of focal plaque-like
PrPd accumulations that lacked any discernable amyloid fibrils by electron microscopy. PrPd
surrounding mature plaques could be found in the absence of fibrillar amyloid apparently
still attached to the plasma-membranes of cells and processes. Similarly, newly forming
plaques appeared to be generated by similar interactions also at the plasma-membrane of
PrPc expressing cells. These observations indicate that new plaques continue to be seeded
and mature plaques continue to grow even after more than 600 days after challenge. Plaques
appear to be initiated by a process in which sub-fibrillar PrPd aggregates (proto-filaments or
oligomers) spread through the extracellular space to recruit and convert new PrPc molecules
that are still attached to membranes.
In vitro studies of the PrPc-PrPres conversion reaction have shown that microsomal PrPc
attached to detergent resistant membranes of neuroblastoma cells was not converted by
simple incubation with microsomes containing membrane attached PrPres (1). Conversion of
PrPc was only achieved when PrPc and PrPres were placed in the same membrane plane by
fusing microsomal PrPc with other membranes containing PrPres. These data suggested that
seed PrPres required to be inserted into microsomal membranes prior to the induction of new
PrPres molecules (1). Our observations agree with these in vitro data and suggest that in situ,
the PrPc substrate for conversion is retained at the plasma-membrane where it is converted
by exogenously derived oligomers of PrPd. The electron microscopy does not indicate
whether exogenous PrPd first inserts into the membrane prior to seeded conversion of new
PrPc molecules but membrane insertion of soluble, globular, pre-fibrillar amyloid oligomers
appear to be an intrinsic property of different amyloid proteins (27).
While in vitro and in vivo data agree that seeded conversion of PrPc to PrPd or PrPres
appears to be initiated by contact between PrPd or PrP aggregates and membrane localised
PrPc, this is unlikely to be the mechanism which supports plaque growth. Studies of
microsomal PrPc show that conversion to PrPres may also occur when PrPc is released from
membranes by cleavage of the glycophosphatidylinositol (GPI) anchor that attaches it to the
outer cell membrane (1). However, other in vitro approaches have suggested that the release
of PrPc from membranes of neuroblastoma cells may actually inhibit the formation of PrPres
(5). Large, and numerous plaques may be found in scrapie infected mice engineered to
produce PrPc molecules lacking the GPI anchor (7). As PrPc is not retained at cell
membranes in this model it cannot be converted there and plaques formed in these
anchorless mice are formed by soluble forms of PrPc released to the extracellular space that
subsequently aggregate in and around blood vessels. In the 101LL-8a mouse we can also
infer continued growth of large, immobile, plaques at their periphery where there are few
cellular processes with attached membrane PrPc. It is likely therefore that some PrPc
molecules or newly formed oligomers of PrPd may be released from membranes to continue
the growth of 101LL-8a plaques by adding onto the ends of immobilised amyloid fibrils
within the extracellular space.
The plaques which form in the infectious TSEs such as murine 87V scrapie are invariably
uni-centric and appear to form initially at the plasma membranes of dendrites (19). Although
multiple plaques may form along the length of a dendrite, scrapie plaques, unlike GSS
plaques, are not conspicuously multi-centric. Multi-centric plaques in 101LL-8a mice
mostly consisted of a single large core with several smaller satellite sub-units surrounding
them. The sub-unit satellites of multi-centric plaques are probably formed by the spread of
oligomers fragmenting from the main plaque and spreading through the interstitial space
until they are stabilised in situ following new conversion reactions with PrPc molecules on
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plasma-membranes of adjacent cells. The present observations suggest that the conversion
of PrPc to amyloid possesses several steps that are common to both 87V scrapie and
101LL-8a. These steps are the conversion of PrPc to PrPd at the cell membranes, the release
of converted PrPd into the extracellular space and the subsequent ordering of PrPd
aggregates into large bundles of amyloid fibrils. However, both the gross arrangement of
amyloid plaques and the nature of the membrane changes present in 87V scrapie point to the
existence of other distinguishing disease processes.
In scrapie of sheep, BSE of cattle and feline spongiform encephalopathy as well as in
experimental scrapie models of mice, there are a number of distinctive membrane changes
that are both directly linked to PrPd and appear to be unique to TSE disease (10, 23, 24, 25).
These changes, which include the abnormal membrane protrusions or microfolds, and spiral
membrane invaginations of axon terminals illustrated in 87V scrapie were absent from
101LL-8a mice. The PG14 mouse is another transgenic line which mimics a GSS insertional
mutation of PrP and it also lacks these membrane changes (17). The PG14 mouse is also not
infectious to wild type mice or to other mice over-expressing the same mutation (9). Thus
TSE specific membrane pathology is found only in infectious TSEs.
Dystrophic axons were conspicuous around plaques of 101LL-8a mice. Dystrophic
processes are also prominent around the cerebrovascular plaques of the scrapie infected
anchorless mouse (7); the stellate plaques formed in 87V scrapie (present observations and
(19) ) as well as several other human prion diseases and murine models (26, 30). Although
rare dystrophic neurites are also found in normal brain tissue, they are increased in several
chronic non-prion human neurodegenerative diseases (30) and are a particular feature
associated with Alzheimer’s disease plaques(31). Thus dystrophic neurites are consistently
present both in prion and in non-prion disorders where abundant amyloid is formed
irrespective of the protein composition of the amyloid. While the mice in this study did not
get sick the scrapie infected GPI anchorless mice do so, but with clinical signs and disease
progression not typical of the RML scrapie strain used to infect them (4, 8). We suggest that
amyloid may result in degenerative disease processes that may result in neurological deficits
in their own right. Dystrophic neurites and Wallerian-type axonal degeneration are evidence
of this amyloid related damage. However, the 101LL-8a mice did not show clinical disease
probably because of the relative infrequency of plaque formation. As many naturally
occurring infectious TSEs diseases do not form plaques it is unlikely that neurological
deficits in the infectious prion diseases are significantly related to such changes.
The role of glial cells in the genesis and maintenance of plaques in Alzheimer’s disease has
been questioned over many years. According to some, microglia are instrumental in
assembling fibrils for the formation of both scrapie and Aß amyloid plaques (45). In the
101LL-8a mouse both activated microglia and reactive astrocytes were prominent at the
periphery of plaques where amyloid bundles could be seen engulfed by highly indented
microglial membranes. However, activated microglia are absent where PrPd was confined
solely to membranes and also from some plaques that were contained entirely within white
matter of the corpus callosum. These observations suggest those microglial cells are not
essential for PrPc–PrPd conversion or for arranging PrPd into highly ordered fibrils. The
generation of Aß plaques has been studied in APP transgenic mice crossed with other
transgenic mice expressing a chemically activated microglial suicide gene (15). In this
Alzheimer’s disease model microglial cells were ablated without effect on numbers of
plaques over the course of disease suggesting that microglia are neither necessary to initiate
nor to maintain Aß plaques. Thus microglia do not appear to be necessary for generation of
plaques of 101LL-8a mice nor murine Aß plaques. Similarly, in the APP mouse model the
numbers of dystrophic neurites were not altered in the presence of activated microglial cells
suggesting the cytokines released by glia do not play a significant part in their origins (15).
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Although the highest expression of PrPc appears to be on neurons (32), the source of PrPc
for conversion into new amyloid plaques or to continue growth of existing plaques in
101LL-8a mice may involve several cell types. Plaques that are entirely contained within the
corpus callosum have contact only with astrocytes, oligodendroglia, and cells surrounding
blood vessels. Immuno-labelling for PrPd at extreme plaque peripheries showed membrane
associated PrPd on the plasmalemmas of oligodendroglia and astrocytes. Where plaques
extended to the stratum oriens of the hippocampus, plasmalemmal labelling was found on
neurites, including dendrites and possibly also axons. Thus PrPc substrate for conversion to
PrPd could be provided by oligodendroglia, astrocytes or neurites.
Previous studies of the nature of amyloid plaques in GSS patients had shown that the
amyloid is composed only of protein derived from the mutant allele (41). Other studies have
suggested that the non-mutant allele may also be involved and may influence disease
phenotype, including the pathological phenotype of some GSS P102L patients (44).
However, it is not clear whether this latter study is relevant to the current study as analysis
of plaques generating 8kDa fragments is not mentioned. In other immunohistochemical
studies of the plaques of GSS patients, including GSS P102L, it was found that PrP
antibodies recognising N terminal epitopes failed to label plaque cores (13, 16, 28, 37). This
has led some authors to suggest that amyloid plaques were initially composed of full length
PrPres that became progressively truncated. In contrast, both the core and the periphery of
plaques formed in infectious TSEs are labelled with antibodies to both N and C terminal
amino acids (21, 22). In the present study none of three PrP antibodies used at the light
microscopy level labelled the cores of 101LL-8a plaques but the same antibodies labelled
core fibrils when immunogold electron microscopy was performed. When compared with
87V plaques individual fibrils of 101LL-8a plaques are more densely packed suggesting that
the absence of core staining of 101LL-8a plaques at light microscopy may be due to poor
antibody penetration of these latter plaques. It would therefore appear likely that fibrils in
101LL-8a plaques are formed from full length PrP protein as they are in 87V scrapie.
In this study we have shown that small PrPd seeds can drive in situ conversion of PrPc
located on cell membranes. Such conversion is not restricted by cell type but the further
growth of amyloid fibrils appears to require release of pre-formed PrPd into the extracellular
space. PrPc conversion and growth of amyloid fibrils can occur without generating TSE
infectivity, whereas the membrane changes that are found in truly infectious TSEs are not
present in association with these amyloid structures.
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Figure 1.
Plaques in the corpus callosum and adjacent hippocampus of 101LL-8a mice and VM mice
with 87V scrapie.
a Mature plaques with an irregular contour and showing central unstained core. Plastic
embedded 1 μm thick section labelled with Saf 84 Bar = 16μm
b PrPd labelling partly surrounding a reactive astrocyte within the corpus callosum. No
amyloid was visible in a serial 1μm thick section stained with toluidine blue. Plastic
embedded 1 μm thick section labelled with Saf 84 Bar=14 μm
c,d Semi-serial sections of a 101LL-8a mouse showing strong labelling of the periphery of
amyloid plaques with R20 (c) and R24 (d) recognising C and N terminal sequences of the
PrP protein respectively. Bar=64 μm
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e,f; There is no such separate labelling of periphery and core plaques in 87V scrapie with
R20 (e) and R24 (f) Bar=32 μm
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Figure 2.
Electron microscopy of plaques of 101LL-8a mice.
a) the centre of a large plaque showing dense uniform amyloid fibrils arranged in
interweaving bundles that virtually exclude all other cellular elements. Bar=225nm
b) The periphery of a large plaque showing infiltration of groups of amyloid fibrils between
neuritic and glial processes. Many of the processes belong to astrocytes, identified by the
presence of glycogen granules (arrow heads) and the paucity of other sub-cellular
organelles. Bar=470nm
c) Two sub-units of a multicentric plaque that was mainly located in grey matter of the
Stratum Oriens and which consisted of more than 5 sub-units. Each sub-unit is of similar
dimensions, and is surrounded by microglial processes (m). Bar=430nm
d) A small sub-unit of a multicentric plaque. This plaque consists of only a few amyloid
fibres within the extracellular space. These fibres are already isolated from neural elements
within the adjacent gray matter by astrocytic processes, characterised by their glycogen
granules and the paucity of other organelles. Bar =1000nm
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e) Detail of D showing the sparse number of amyloid fibres in tangential and transverse
section (arrowheads). A, Astrocytic processes. Bar=165nm
f) Dystrophic neurites within myelinated processes adjacent to a large plaque. One
dystrophic neurite occupies one side of a paranode (p) while the opposite side appears
unaffected. Bar=920nm
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Figure 3.
Immunogold labelling for PrPd in 101LL-8a mice.
a) Despite the paucity of labelling of plaque cores by light microscopy, the core of a mature
plaque shows good immunogold labelling for PrPd. Bar=138nm.
b) The periphery of a large plaque with one of several smaller adjacent satellite plaques is
shown. Both parent and satellite plaques are labelled for PrPd. Bar=1600nm
c) PrPd labelling is present around an oligodendrocyte located at the extreme periphery of a
large plaque, the edge of which is seen at the bottom right. (Box indicates area shown in
inset (inset: showing the localisation of PrPd on the membranes of the oligodendrocyte).
Bar=1600nm
d) Extreme periphery of a plaque. No amyloid fibrils are visible but PrPd labels the plasma-
membrane membranes of several processes including that of a dendrite (D) and an astrocyte
(A). Bar=336nm
e) A plaque identified by immunolabelling in the plastic section (inset) shows no
morphological change by uranyl acetate/lead citrate staining but in the corresponding
location, there is membrane PrPd labelling on several neuritic processes or in the associated
extracellular space. Bar=290nm
Immunogold for PrPd using 1A8 antibody.
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Figure 4.
Features of plaques in 87V infected VM mice.
a) PrPd labelling of small numbers of amyloid fibrils in longitudinal, transverse and
tangential section in the extracellular space at the periphery of a large unicentric plaque. Bar
= 275nm
b) PrPd labelling on the plasma lemma of neurites and glial processes at the extreme
periphery of a unicentric plaque. All processes have abnormal irregular contours. No fibrils
are evident. Bar =160nm
c) PrPd labelling of a lysosome within a microglial cell body near the edge of a plaque
shown only by sparse PrPd labelling on cell membranes of adjacent processes Bar=200nm
d and e) PrPd labelling of small membrane protrusions or microfolds in transverse (arrow in
d) and longitudinal (arrows in e) section. d and e Bars =200nm.
f) PrPd labelling associated with a coated spiral membrane inclusion in an axon terminal.
The continuity of the inclusion with the axonal plasma-membrane is not in the plane of
section. The abnormal coated vesicles that are associated with these invaginations (arrow) is
also clearly evident. The insert shows a further axon terminal membrane invagination. In
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this non-immunolabelled section the continuity with the external plasma-membare and the
spiral nature of the membrane invagination is evident as are intact synaptic vesicles
confirming the process as an axon terminal. Bar=180nm (Bar in insert = 250nm)
g) Part of an abnormal dendrite lacking organelles with an uncoated spiral plasma-
membrane invagination. The section is not immunolabelled. Bar = 280nm
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